PRECISION BIOSCIENCES INCDTILEarnings & Financial Report
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
DTIL Q3 2025 Key Financial Metrics
Revenue
$13.0K
Gross Profit
N/A
Operating Profit
$-20.7M
Net Profit
$-21.8M
Gross Margin
N/A
Operating Margin
-158976.9%
Net Margin
-167476.9%
YoY Growth
-97.7%
EPS
$-1.84
Financial Flow
PRECISION BIOSCIENCES INC Q3 2025 Financial Summary
PRECISION BIOSCIENCES INC reported revenue of $13.0K for Q3 2025, with a net profit of $-21.8M (-167476.9% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $13.0K |
|---|---|
| Net Profit | $-21.8M |
| Gross Margin | N/A |
| Operating Margin | -158976.9% |
| Report Period | Q3 2025 |
PRECISION BIOSCIENCES INC Annual Revenue by Year
PRECISION BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2024 revenue was $68.7M).
| Year | Annual Revenue |
|---|---|
| 2024 | $68.7M |
| 2023 | $48.7M |
| 2022 | $25.1M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $17.6M | $49.9M | $576000 | $638000 | $29000 | $18000 | $13000 |
| YoY Growth | -33.6% | 100.3% | 152.2% | -95.6% | -90.9% | -99.8% | -100.0% | -97.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $159.8M | $184.7M | $165.8M | $153.3M | $136.4M | $124.4M | $108.9M | $93.5M |
| Liabilities | $140.9M | $147.5M | $91.1M | $88.4M | $80.0M | $75.1M | $74.9M | $76.9M |
| Equity | $18.9M | $37.2M | $74.7M | $64.9M | $56.4M | $49.3M | $34.1M | $16.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-8.4M | $-19.0M | $-14.9M | $-5.9M | $-18.7M | $-19.1M | $-20.3M | $-15.3M |
More Companies
CRSP
CRISPR Therapeutics AG
Revenue
$864.0K
Net Profit
$-130.6M
GRAL
GRAIL, Inc.
Revenue
$36.2M
Net Profit
$-89.0M
RCUS
Arcus Biosciences, Inc.
Revenue
$6.0M
Net Profit
$-135.0M
TXG
10x Genomics, Inc.
Revenue
$166.0M
Net Profit
$-16.3M
DFTX
Mind Medicine (MindMed) Inc.
Revenue
$906.0K
Net Profit
$-23.9M
PACB
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Revenue
$38.4M
Net Profit
$-38.0M
ASMB
ASSEMBLY BIOSCIENCES, INC.
Revenue
$10.8M
Net Profit
$-9.2M